SMN1 and cardiac arrhythmia: Prior to the introduction of treatments, such as nusinersen and risdiplam, which modify SMN2 gene regulation to increase functional SMN expression, the impact on concomitant health issues in SMA patients following respiratory assistance, and thus extended life expectancy, has been previously highlighted (10) and included development of heart arrhythmia (bradycardia).